BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 7, 2009
View Archived Issues
Snapshots: ICAAC presentations on Novexel's novel beta-lactamase inhibitor NXL-104
Read More
NovaBiotics details activity and toxicology studies of onychomycosis treatment NP-213
Read More
Pharmacokinetics, tolerability of novel bevirimat tablet formulation assessed in HIV patients
Read More
IMC-1121B is well tolerated as second-line treatment in metastatic RCC
Read More
MHRA approves continued development of MediGene's RhuDex for rheumatoid arthritis
Read More
Zebinix launched in Germany and Austria
Read More
Merck & Co presents data on telcagepant evaluation in migraine
Read More
MVA-5T4 fails to meet primary endpoint in TRIST survival trial
Read More
GSK and XenoPort report phase II results for GSK-1838262 in postherpetic neuralgia
Read More
Santhera acquires Oy Juvantia and receives final upfront payment from Biovail
Read More
FDA panel supports approval of GSK's Votrient for advanced renal cell carcinoma
Read More
GlaxoSmithKline files sNDA with FDA for Avodart in prostate cancer
Read More
Biotron completes phase Ib/IIa study of BIT-225 in hepatitis C
Read More
Peregrine reports results from phase II bavituximab trial in lung cancer
Read More
Physiology or Medicine 2009 Nobel Prize awarded to U.S. scientists for work on telomeres
Read More
Novartis and Xenon Pharmaceuticals claim SCD inhibitors for the treatment of dyslipidemia
Read More
Tritium-labeled sigma-2 receptor agonists presented by Italian scientists for cancer diagnosis
Read More
Chugai Pharmaceutical describes novel PI3Kalpha inhibitors as oncolytics
Read More
Onglyza receives marketing authorization in Europe for type 2 diabetes
Read More
R-Tech Ueno begins early phase II trial of RK-023 for male pattern baldness
Read More
Vantia Therapeutics' VA-111913 enters phase II proof-of-concept trial for dysmenorrhea
Read More
Vernalis commences pilot study of V-3381 in patients with chronic cough
Read More
Pharmasset to advance PSI-879 into preclinical development for hepatitis C
Read More
ThromboGenics reports results of microplasmin trial in diabetic macular edema
Read More
Topica reports phase II results for luliconazole for athlete's foot
Read More
Transdel presents phase III results for lead topical pain drug, Ketotransdel
Read More